2,122 results on '"cardio-renal syndrome"'
Search Results
2. Peritoneal Ultrafiltration in Cardio Renal Syndrome. (PURE)
- Published
- 2024
3. Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study (SGLT2i in CRS)
- Author
-
American Heart Association
- Published
- 2024
4. Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance
- Published
- 2024
5. The Aortix CRS Pilot Study
- Author
-
Procyrion Australia Pty Ltd
- Published
- 2024
6. The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 (TREAT-CRS)
- Author
-
Nattachai Srisawat ,M.D., Professor
- Published
- 2024
7. Kidney Sodium Content in Cardiorenal Patients
- Author
-
Chris McIntyre, Professor of Medicine, Medical Biophysics and Pediatrics
- Published
- 2024
8. Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome (ANX-042 Aim 1)
- Author
-
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), and Paul M. McKie, M.D., PI
- Published
- 2024
9. A new animal model of cardiorenal syndrome could be established by inducing heart failure through coronary artery ligation in spontaneously hypertensive rats.
- Author
-
Zhou, Biye, Zhao, Jinbao, and Li, Dong
- Subjects
- *
LIPOCALIN-2 , *BRAIN natriuretic factor , *CARDIO-renal syndrome , *CYSTATIN C , *ANGIOTENSIN II , *GLUTATHIONE peroxidase - Abstract
In rats with unilateral nephrectomy and cardiac dysfunction, renal function deteriorates at an accelerated rate, as evidenced by increased proteinuria. Whether myocardial infarct-induced heart failure (HF) exacerbates renal injury in hypertensive rats with mild renal injury has not been reported. Rats underwent either coronary ligation or sham surgery. Thirty spontaneously hypertensive rats (SHRs) aged 8 weeks were randomly divided into two groups. Group 1 was the sham group, in which the rats underwent thoracotomy without ligation of the coronary artery. Group 2 underwent coronary artery ligation. The rats in group 2 underwent coronary artery ligation on week 0. The experiment lasted 12 weeks. Urine was collected in metabolic cages over a 24-h period. Urine was collected from the rats 2 days before the end of the experiment, and the ratio of urinary protein to urinary creatinine was measured in the clinical laboratory. All rats were examined by echocardiogram one day before the end of the experiment. On the last day of the experiment, blood was collected and sent to the laboratory for analysis. Hematoxylin–eosin (HE) and periodic acid-Schiff (PAS) staining were performed on heart and kidney sections. The ejection fraction in group 2 was lower than that in group 1 (P < 0.001). The urinary albumin to creatinine ratio in group 2 was greater than that in group 1 (P < 0.001). The urea and creatinine levels in group 1 were significantly lower than those in group 2 (P < 0.01). The levels of brain natriuretic peptide (BNP), neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C were greater in the second group than in the first group (P < 0.05). The interleukin-1β (IL-1β) and interleukin-6 (IL-6) levels in group 2 were significantly greater than those in group 1 (P < 0.001). The malondialdehyde (MDA) levels in Group 2 were greater than those in Group 1 (P < 0.01). The glutathione peroxidase (GSH-Px) levels in Group 2 were lower than those in Group 1 (P < 0.05). The level of angiotensin II (AT-II) in group 1 was lower than that in group 2 (P < 0.001). Cardiac dysfunction secondary to myocardial infarction could induce cardiorenal interactions in SHRs. It could be interpreted by the activation of oxidative stress, changes in inflammation and alteration of renin–angiotensin–aldosterone system. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and kidney dysfunction.
- Author
-
Núñez-Marín, Gonzalo, Palau, Patricia, Domínguez, Eloy, de la Espriella, Rafael, López, Laura, Flor, Cristina, Marín, Paloma, Lorenzo, Miguel, Miñana, Gema, Bodí, Vicent, Sanchis, Juan, and Núñez, Julio
- Subjects
- *
BRAIN natriuretic factor , *AEROBIC capacity , *CARDIO-renal syndrome , *NATRIURETIC peptides , *CHRONIC kidney failure - Abstract
Background Heart failure with preserved ejection fraction (HFpEF) often coexists with chronic kidney disease (CKD). Exercise intolerance is a major determinant of quality of life and morbidity in both scenarios. We aimed to evaluate the associations between N-terminal pro-B-type natriuretic peptide (NT-proBNP) and carbohydrate antigen 125 (CA125) with maximal aerobic capacity (peak VO2) in ambulatory HFpEF and whether these associations were influenced by kidney function. Methods This single-centre study prospectively enrolled 133 patients with HFpEF who performed maximal cardiopulmonary exercise testing. Patients were stratified across estimated glomerular filtration rate (eGFR) categories (<60 ml/min/1.73 m2 versus ≥60 ml/min/1.73 m2). Results The mean age of the sample was 73.2 ± 10.5 years and 56.4% were female. The median of peak VO2 was 11.0 ml/kg/min (interquartile range 9.0–13.0). A total of 67 (50.4%) patients had an eGFR <60 ml/min/1.73 m2. Those patients had higher levels of NT-proBNP and lower peak VO2, without differences in CA125. In the whole sample, NT-proBNP and CA125 were inversely correlated with peak VO2 (r = −0.43, P < .001 and r = −0.22, P = .010, respectively). After multivariate analysis, we found a differential association between NT-proBNP and peak VO2 across eGFR strata (P for interaction = .045). In patients with an eGFR ≥60 ml/min/1.73 m2, higher NT-proBNP identified patients with poorer maximal functional capacity. In individuals with eGFR <60 ml/min/1.73 m2, NT-proBNP was not significantly associated with peak VO2 [β = 0.02 (95% confidence interval −0.19–0.23), P = .834]. Higher CA125 was linear and significantly associated with worse functional capacity without evidence of heterogeneity across eGFR strata (P for interaction = .620). Conclusions In patients with stable HFpEF, NT-proBNP was not associated with maximal functional capacity when CKD was present. CA125 emerged as a useful biomarker for estimating effort intolerance in HFpEF irrespective of the presence of CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study.
- Author
-
Guo, Zihan, Ding, Yunlan, Wang, Mengmeng, Zhai, Qing, Liu, Jiyong, and Du, Qiong
- Subjects
- *
GRAFT versus host disease , *CEREBRAL hemorrhage , *CARDIO-renal syndrome , *CHIMERIC antigen receptors , *INTRACRANIAL hemorrhage - Abstract
In this study, we compared the similarities and differences in adverse events (AEs) among CAR T-cell products through signal mining via the FDA Adverse Event Reporting System (FAERS) and identified unknown AEs to provide a reference for safe clinical medication. Data from the FAERS database spanning from the fourth quarter of 2017 to the first quarter of 2024 were extracted. Signals were identified using the reporting odds ratio (ROR) method and the Medicines and Healthcare Products Regulatory Agency (MHRA) method. A total of 11,386 AE reports related to six CAR T-cell products were selected. The top three categories of AEs reported were nervous system disorders, immune system disorders, and general disorders and administration site conditions. However, there were variations in the AE spectra among the different CAR T-cell products. The BCMA-targeting drugs idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (Cilta-cel) were found to be associated with parkinsonism, which were not observed in CD19-targeting drugs. Tisagenlecleucel (Tisa-cel) and axicabtagene ciloleucel (Axi-cel) exhibited cerebrovascular accident-related AEs, graft versus host disease, and abnormal coagulation indices. Cilta-cel was associated with cerebral hemorrhage, intracranial hemorrhage, cranial nerve disorder, and facial nerve disorder. Cardiopulmonary toxicity, including hypoxia, tachypnoea, cardiorenal syndrome, and hypotension, exhibited strong signal intensities and considerable overlap with CRS. The number of positive signals for cardiopulmonary toxicity associated with drugs targeting CD-19 is greater. Clinicians should assess patients prior to medication and closely monitor their vital signs, mental status, and laboratory parameters during treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. A Systematic Review of Uremic Toxin Concentrations and Cardiovascular Risk Markers in Pediatric Chronic Kidney Disease.
- Author
-
Dalpathadu, Heshini, Salim, Aly Muhammad, Wade, Andrew, and Greenway, Steven C.
- Subjects
- *
CARDIO-renal syndrome , *CHRONIC kidney failure , *CARDIOTOXICITY , *PERITONEAL dialysis , *CHILD patients - Abstract
Chronic kidney disease (CKD) can lead to cardiac dysfunction in a condition known as cardiorenal syndrome (CRS). It is postulated that the accumulation of uremic toxins in the bloodstream, as a consequence of declining kidney function, may contribute to these adverse cardiac effects. While CRS in adults has been extensively studied, there is a significant knowledge gap with pediatric patients. Uremic toxin levels in children remain inadequately characterized and quantified compared to adults. This review aims to systematically evaluate the association between uremic toxin concentrations and cardiac changes in pediatric CRS and to examine the impact of different dialysis modalities, specifically hemodialysis and peritoneal dialysis, on uremic toxin clearance and cardiovascular parameters. To address this, we conducted a systematic literature search of PubMed, following PRISMA guidelines. We used the terms "uremic toxins" and "cardiorenal syndrome" with variations in syntax to search for studies discussing the relationship between uremic toxin levels in CKD, the subsequent impact on cardiac parameters, and the emergence of cardiac dysfunction. Full-text articles written in English, conducted on humans aged from birth to 18 years, and published until December 2021 were included. A comprehensive literature search yielded six studies, and their risk of bias was assessed using JBI Critical Appraisal Checklists. Our systematic review is registered on PROSPERO, number CRD42023460072. This synthesis intends to provide an understanding of the role of uremic toxins in pediatric CRS. The findings reveal that pediatric patients with end-stage CKD on dialysis exhibit elevated uremic toxin levels, which are significantly associated with cardiovascular disease parameters. Additionally, the severity of CKD correlated with higher uremic toxin levels. No conclusive evidence was found to support the superiority of either hemodialysis or peritoneal dialysis in terms of uremic toxin clearance or cardiovascular outcomes. More pediatric-specific standardized and longitudinal studies are needed to develop targeted treatments and improve clinical outcomes and the quality of life for affected children. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. The Need to Identify Novel Markers for Early Renal Injury in Cardiorenal Syndrome.
- Author
-
Lisa, Anna, Carbone, Federico, Liberale, Luca, and Montecucco, Fabrizio
- Subjects
- *
CARDIO-renal syndrome , *ACUTE kidney failure , *CHRONIC kidney failure , *HEART failure , *INFLAMMATION - Abstract
The term "Cardiorenal Syndrome" (CRS) refers to the complex interplay between heart and kidney dysfunction. First described by Robert Bright in 1836, CRS was brought to its modern view by Ronco et al. in 2008, who defined it as one organ's primary dysfunction leading to secondary dysfunction in the other, a view that led to the distinction of five different types depending on the organ of primary dysfunction and the temporal pattern (acute vs. chronic). Their pathophysiology is intricate, involving various hemodynamic, neurohormonal, and inflammatory processes that result in damage to both organs. While traditional biomarkers have been utilized for diagnosing and prognosticating CRS, they are inadequate for the early detection of acute renal damage. Hence, there is a pressing need to discover new biomarkers to enhance clinical outcomes and treatment approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Histopathology of congestive nephropathy: a case description and literature review.
- Author
-
Husain‐Syed, Faeq, Rangaswami, Janani, Núñez, Julio, Skrzypek, Susanne, Jux, Christian, Gröne, Hermann‐Josef, and Birk, Horst‐Walter
- Subjects
CARDIO-renal syndrome ,ACUTE kidney failure ,LITERATURE reviews ,HEART failure ,CELL differentiation ,KIDNEY diseases ,INTRA-abdominal hypertension - Abstract
Congestive nephropathy is an underappreciated manifestation of cardiorenal syndrome and is characterized by a potentially reversible kidney dysfunction caused by a reduced renal venous outflow secondary to right‐sided heart failure or intra‐abdominal hypertension. To date, the histological diagnostic criteria for congestive nephropathy have not been defined. We herein report a case of acute renal dysfunction following cardiac allograft failure and present a review of the relevant literature to elucidate the current understanding of the disease. Our case demonstrated that congestion‐driven nephropathy may be histopathologically characterized by markedly dilated veins and peritubular capillaries, focally accentuated low‐grade acute tubular damage, small areas of interstitial fibrosis, and tubular atrophy on a background of normal glomeruli and predominantly normal tubular cell differentiation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Fractional excretion of urea nitrogen can identify true worsening renal function in patients with heart failure.
- Author
-
Watanabe, Yukihiro, Kubota, Yoshiaki, Nishino, Takuya, Tara, Shuhei, Kato, Katsuhito, Hayashi, Daisuke, Matsuda, Junya, Miyachi, Hideki, Tokita, Yukichi, Iwasaki, Yu‐ki, and Asai, Kuniya
- Subjects
CARDIO-renal syndrome ,PATIENT readmissions ,ACUTE kidney failure ,HOSPITAL admission & discharge ,HEART failure patients - Abstract
Aims: Fractional excretion of urea nitrogen (FEUN), used to differentiate the cause of acute kidney injury, has emerged as a useful fluid index in patients with heart failure (HF). We hypothesized that FEUN could be useful in identifying worsening renal function (WRF) associated with poor outcomes in patients with acute HF (AHF). Methods and results: Overall, 1103 patients with AHF (median age, 78 years; male proportion, 60%) were categorized into six groups according to the presence of WRF and FEUN values (low, ≤32.1%; medium, >32.1% and ≤38.0%; and high, >38.0%) at discharge. WRF was defined as an increase of ≥0.3 mg/dL in the serum creatinine level from admission to discharge. FEUN was calculated by the following formula: (urinary urea × serum creatinine) × 100/(serum urea × urinary creatinine). The cut‐off values for low, medium, and high FEUN were based on a previous study. The primary outcome of this study was HF readmission after hospital discharge. During the 1 year follow‐up, 170 HF readmissions occurred. Kaplan–Meier analysis revealed significantly higher HF readmission rates in patients with WRF than in those without WRF (log‐rank test, P < 0.001). Additionally, among patients with WRF, HF readmission rates were lowest in those with medium FEUN values, followed by those with low FEUN values and those with high FEUN values. On multivariable analysis, the presence of WRF with low or high FEUN values was independently associated with increased HF readmission, as compared with the absence of WRF with medium FEUN values. Notably, no association was noted between WRF with medium FEUN values and HF readmission. Conclusions: The prognostic impact of WRF was significantly mediated by the FEUN values and was associated with worse outcomes only when the FEUN values were either low or high. Our study suggests that FEUN can identify prognostically relevant WRF in patients with AHF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Improvement in Echocardiographic Indexes of Systolic Heart Failure Post-Kidney Transplantation: A Retrospective Analysis.
- Author
-
Skalsky, Keren, Perl, Leor, Rozen Zvi, Benaya, Atamna, Mohamad, Kornowski, Ran, Nesher, Eviatar, Rahamimov, Ruth, Ben Gal, Tuvia, Shapira, Yaron, Shiyovich, Arthur, and Steinmetz, Tali
- Subjects
- *
CARDIO-renal syndrome , *CHRONIC kidney failure , *KIDNEY transplantation , *CARDIOVASCULAR diseases risk factors , *HEART transplantation , *HEART failure - Abstract
Introduction: End-stage renal disease is a major risk factor for cardiovascular morbidity and mortality, which can be partially eliminated by kidney transplantation. Systolic heart failure might be considered contraindication for kidney transplant, although some patients demonstrate myocardial recovery post-transplant. We aimed to identify and characterize the phenomenon of reverse myocardial remodeling in kidney transplanted patients. Methods: The study is a retrospective cohort of patients undergoing kidney transplants between 2016 and 2019 (n = 604) at Rabin Medical Center. Patients were assessed according to availability of two echocardiographic examinations: pre- and post-kidney transplant. The change in estimated ejection fraction (EF) and possible predictors of myocardial recovery were examined. Results: Data of 293 patients was available for the final analysis. Eighty-one (28%) patients had a LVEF improvement equal to or above 5%, whereas 36 (12%) patients had a LVEF improvement of 10% or more post-transplantation. Twenty-five patients (8.5%) had moderate or severe systolic heart failure with LVEF reduced to 40% or less at baseline. 13 of them (52%) had a LVEF improvement of ≥5%, and 10 patients (40%) had an improvement of ≥10% in their EF. Cox regression analyses identified female gender as the only independent variable associated with LVEF improvement of at least 10%. Conclusion: Renal transplantation might lead to improved LV systolic function in some patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia.
- Author
-
Mohammedsaeed, Walaa and Alghamdi, Zain J.
- Subjects
CARDIO-renal syndrome ,TYPE 2 diabetes ,HEPATORENAL syndrome ,CIRRHOSIS of the liver ,DISEASE risk factors ,HYPERTENSION - Abstract
Objectives: To evaluate the correlation between different attributes, levels of biomarkers, and the probability of developing cardiorenal syndrome (CRS) in patients who have been diagnosed with type 2 diabetes mellitus (T2DM) and liver cirrhosis (LC). The hypothesis suggests that liver illness may be linked to renal impairment, cardiac dysfunction, and the development of cardiorenal syndrome Methods: The current study retrospectively assessed the medical records of patients who had LC and T2DM diagnoses and were hospitalized at Al Madina Al Munwara hospitals in 2022 and 2023. Original Article Results: This research investigated T2DM patients with physician-confirmed to have LC. Poor glycemic control is indicated by high blood glucose and glycated hemoglobin (HbA1c) readings in research participants. High blood pressure, atherogenic plasma indicator (AIP), and obesity plagued most of these individuals. High creatinine, moderate estimated Glomerular Filtration Rate (eGFR) decline, and a modest urinary albumin-to-creatinine (UACR) rise were the most prevalent variables in LC and T2DM patients. Cardiorenal syndrome risk factors, including elevated blood pressure, triglyceride levels, body mass index (BMI), and high-sensitivity C-reactive protein (hs-CRP) concentrations, were identified through logistic regression. It has been demonstrated that the prevalence of these risk factors increases with age; women may be at a greater risk for developing CRS. Specific biomarker evaluations classified 108 (22.6%) LC and T2DM patients at high risk for chronic kidney disease (CKD), 100 (20%) at risk for cardiovascular disease (CVD), and 91 (18.2%) at risk for CRS. Conclusion: The current assessment included 500 patients with T2DM and LC. The risk factors for CRS identified in this study included elevated cholesterol and triglyceride levels, high BMI, and elevated blood pressure, with age being a significant factor, particularly in female patients. Early identification of these characteristics in patients with LC and T2DM could aid in mitigating the progression of chronic illnesses and their associated complications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Long-term outcomes of acute kidney injury in acute decompensated heart failure: identifying true cardiorenal syndrome and unveiling prognostic significance
- Author
-
Peerapat Thanapongsatorn, Atiwat Tanomchartchai, and Jarin Assavahanrit
- Subjects
acute kidney injury ,cardio-renal syndrome ,chronic renal insufficiency ,heart failure ,mortality ,Internal medicine ,RC31-1245 ,Specialties of internal medicine ,RC581-951 - Abstract
Background Cardiorenal syndrome (CRS) type 1 defined as acute kidney injury (AKI) in acute decompensated heart failure (ADHF), is complicated due to diverse definitions. Recently, a more precise CRS type 1 definition was proposed, mandating concurrent AKI and signs of unimproved heart failure (HF). Our study explores the incidence, predictors, and long-term outcomes of AKI in ADHF under this new definition. Methods A prospective observation study of ADHF patients categorized into the CRS type 1, pseudo-CRS, and non-AKI groups, followed for 12 months. CRS type 1 involved AKI with clinical congestion, while pseudo-CRS included AKI with clinical decongestion (clinical congestion score
- Published
- 2024
- Full Text
- View/download PDF
19. Renal Venous Flow and Cardiac Surgery-associated Acute Kidney Injury
- Author
-
Faeq Husain-Syed, Senior physician
- Published
- 2023
20. Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF) (VOID-HF)
- Published
- 2023
21. SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)
- Author
-
Lenar Yessayan, Professor of Medicine
- Published
- 2023
22. Selective Cytopheretic Device (SCD) Trial
- Author
-
Lenar Yessayan, Professor of Medicine
- Published
- 2023
23. Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome (NEEDED)
- Author
-
EchoNous Inc. and Salvador Lopez Gil, Chief of Hemodialysis Unit
- Published
- 2023
24. Risk factors and early prediction of cardiorenal syndrome type 3 among acute kidney injury patients: a cohort study.
- Author
-
Lin, Hui, Guo, Xiaoyu, Wang, Mengzhu, Su, Xiaole, and Qiao, Xi
- Subjects
- *
CARDIO-renal syndrome , *ACUTE kidney failure , *HEPATORENAL syndrome , *KIDNEY diseases , *COHORT analysis , *DECISION making , *HEART injuries - Abstract
Type 3 cardiorenal syndrome (CRS type 3) triggers acute cardiac injury from acute kidney injury (AKI), raising mortality in AKI patients. We aimed to identify risk factors for CRS type 3 and develop a predictive nomogram. In this retrospective study, 805 AKI patients admitted at the Department of Nephrology, Second Hospital of Shanxi Medical University from 1 January 2017, to 31 December 2021, were categorized into a study cohort (406 patients from 2017.1.1-2021.6.30, with 63 CRS type 3 cases) and a validation cohort (126 patients from 1 July 2021 to 31 Dec 2021, with 22 CRS type 3 cases). Risk factors for CRS type 3, identified by logistic regression, informed the construction of a predictive nomogram. Its performance and accuracy were evaluated by the area under the curve (AUC), calibration curve and decision curve analysis, with further validation through a validation cohort. The nomogram included 6 risk factors: age (OR = 1.03; 95%CI = 1.009–1.052; p = 0.006), cardiovascular disease (CVD) history (OR = 2.802; 95%CI = 1.193–6.582; p = 0.018), mean artery pressure (MAP) (OR = 1.033; 95%CI = 1.012–1.054; p = 0.002), hemoglobin (OR = 0.973; 95%CI = 0.96-–0.987; p < 0.001), homocysteine (OR = 1.05; 95%CI = 1.03–1.069; p < 0.001), AKI stage [(stage 1: reference), (stage 2: OR = 5.427; 95%CI = 1.781–16.534; p = 0.003), (stage 3: OR = 5.554; 95%CI = 2.234–13.805; p < 0.001)]. The nomogram exhibited excellent predictive performance with an AUC of 0.907 in the study cohort and 0.892 in the validation cohort. Calibration and decision curve analyses upheld its accuracy and clinical utility. We developed a nomogram predicting CRS type 3 in AKI patients, incorporating 6 risk factors: age, CVD history, MAP, hemoglobin, homocysteine, and AKI stage, enhancing early risk identification and patient management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review.
- Author
-
Varga, Cecilia R., Cleland, John G.F., Abraham, William T., Lip, Gregory Y.H., Leyva, Francisco, and Hatamizadeh, Parta
- Subjects
- *
CHRONIC kidney failure , *CARDIO-renal syndrome , *CARDIAC pacing , *PATIENT selection , *ARRHYTHMIA , *IMPLANTABLE cardioverter-defibrillators - Abstract
Heart failure and chronic kidney disease are common and clinically important conditions that regularly coexist. Electrophysiologic changes of advanced heart failure often result in abnormal conduction, causing dyssynchronous contraction, and development of ventricular arrhythmias, which can lead to sudden cardiac arrest. In the last 2 decades, implantable cardioverter-defibrillator and cardiac resynchronization therapy devices have been developed to address these complications. However, when the coexisting chronic kidney disease is advanced, the associated pathophysiologic cardiovascular changes can alter the efficacy and safety of those interventions and complicate the management. This review explores the impact of comorbid advanced heart failure and advanced chronic kidney disease on the efficacy and safety of implantable cardioverter-defibrillator and cardiac resynchronization therapy, the currently available evidence, and potential future directions. [Display omitted] • The efficacy and safety of ICD and CRT devices have not been established for patients with advanced CKD, and available data suggest that they may be less favorable than in patients without advanced CKD. • Factors limiting the effectiveness of these devices in patients with advanced CKD include the frequency of nonshockable arrhythmias, increased defibrillation thresholds, noncapture, myocardial fibrosis, coexisting atrial fibrillation, limited use of guideline-directed therapies for heart failure, and relatively high rates of nonarrhythmic mortality. • Randomized trials are needed to improve selection of patients with advanced CKD for these device-based therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Long-Term Renal Function with Cardiac Contractility Modulation Therapy.
- Author
-
Yuecel, Goekhan, Yazdani, Babak, Schreiner, Kristin, Fastner, Christian, Hetjens, Svetlana, Husain-Syed, Faeq, Kruska, Mathieu, Duerschmied, Daniel, Krämer, Bernhard K., Abraham, William T., Akin, Ibrahim, and Kuschyk, Juergen
- Subjects
- *
KIDNEY physiology , *CHRONIC kidney failure , *KIDNEY transplantation , *GLOMERULAR filtration rate , *VENTRICULAR ejection fraction , *ARTIFICIAL implants , *CARDIO-renal syndrome - Abstract
Cardiac implantable electrical devices are able to affect kidney function through hemodynamic improvements. The cardiac contractility modulation (CCM) is a device-based therapy option for patients with symptomatic chronic heart failure (HF) despite optimized medical treatment. The long-term cardiorenal interactions for CCM treated patients are yet to be described.Introduction: CCM recipients (Methods: n = 187) from the Mannheim Cardiac Contractility Modulation Observational Study (MAINTAINED) were evaluated in the long-term (up to 60 months) for changes in serum creatinine, estimated glomerular filtration rate (eGFR), other surrogate markers of kidney function, and the chronic kidney disease (CKD) stage distribution. With regard to kidney function at baseline, the patients were furthermore grouped to either advanced CKD (aCKD, CKD stage ≥3, eGFR≤59 mL/min/1.73 m2,n = 107) or preserved kidney function and mild CKD (pCKD, CKD stages 1–2, eGFR≥60 mL/min/1.73 m2,n = 80). The groups were compared for differences regarding kidney function, New York Heart Association classification (NYHA), biventricular systolic function, HF hospitalizations and other parameters in the long-term (60 months). CKD stage distribution remained stable during the entire follow-up (Results: p = 0.65). An increase in serum creatinine (1.47 ± 1 vs. 1.6±1 mg/dL) with a corresponding decline of eGFR (58.2 ± 23.4 vs. 54.2 ± 24.4 mL/min/1.73 m2, bothp < 0.05) were seen after 60 months but not before for the total cohort, which was only significant in pCKD patients in terms of group comparison. Mean survival (54.3 ± 1.3 vs. 55.3 ± 1.2 months,p = 0.53) was comparable in both groups. Improvements in NYHA (3.11 ± 0.46 vs. 2.94 ± 0.41–2.28 ± 0.8 vs. 1.94 ± 0.6) and LVEF (24.8 ± 7.1 vs. 22.9 ± 6.6–31.1 ± 11.4 vs. 35.5 ± 11.1%) were likewise similar after 60 months (bothp < 0.05). The aCKD patients suffered from more HF hospitalizations and ventricular tachycardias during the entire follow-up period (bothp < 0.05). The kidney function parameters and CKD stage distribution might remain stable in CCM treated HF patients in the long-term, who experience improvements in LVEF and functional status, regardless of their kidney function before. An impaired kidney function might be associated with further cardiovascular comorbidities and more advanced HF before CCM, and could be an additional risk factor of HF complications afterward. [ABSTRACT FROM AUTHOR]Conclusions: - Published
- 2024
- Full Text
- View/download PDF
27. Simultaneous Heart and Kidney Transplantation: A Systematic Review and Proportional Meta-Analysis of Its Characteristics and Long-Term Variables.
- Author
-
Sampaio, Natália Zaneti, Faleiro, Matheus Daniel, Vieira, Laynara Vitória da Silva, Lech, Gabriele Eckerdt, Viana, Sofia Wagemaker, Oliveira Tavares, Clara Pereira, Mattiazzi, Adela D., and Burke II, George W.
- Subjects
- *
HEART transplantation , *KIDNEY transplantation , *KIDNEY failure , *CARDIO-renal syndrome , *CARDIAC patients , *KIDNEY diseases - Abstract
Patients with end-stage heart disease who undergo a heart transplant frequently have simultaneous kidney insufficiency, therefore simultaneous heart and kidney transplantation is an option and it is necessary to understand its characteristics and long-term variables. The recipient characteristics and operative and long-term variables were assessed in a meta-analysis. A total of 781 studies were screened, and 33 were thoroughly reviewed. 15 retrospective cohort studies and 376 patients were included. The recipient's mean age was 51.1 years (95% CI 48.52-53.67) and 84% (95% CI 80-87) were male. 71% (95% CI 59-83) of the recipients were dialysis dependent. The most common indication was ischemic cardiomyopathy [47% (95% CI 41-53)] and cardiorenal syndrome [22% (95% CI 9-35)]. Also, 33% (95% CI 20-46) of the patients presented with delayed graft function. During the mean follow-up period of 67.49 months (95% CI 45.64-89.33), simultaneous rejection episodes of both organ allografts were described in 5 cases only. Overall survival was 95% (95% CI 88-100) at 30 days, 81% (95% CI 76-86) at 1 year, 79% (95% CI 71-87) at 3, and 71% (95% CI 59-83) at 5 years. Simultaneous heart and kidney transplantation is an important option for concurrent cardiac and renal dysfunction and has acceptable rejection and survival rates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Unsupervised Cluster Analysis in Patients with Cardiorenal Syndromes: Identifying Vascular Aspects.
- Author
-
de Freminville, Jean-Baptiste, Halimi, Jean-Michel, Maisons, Valentin, Goudot, Guillaume, Bisson, Arnaud, Angoulvant, Denis, and Fauchier, Laurent
- Subjects
- *
CARDIO-renal syndrome , *CLUSTER analysis (Statistics) , *CHRONIC kidney failure , *RENAL replacement therapy , *PERIPHERAL vascular diseases , *HEART failure - Abstract
Background/Objectives: Cardiorenal syndrome (CRS) is a disorder of the heart and kidneys, with one type of organ dysfunction affecting the other. The pathophysiology is complex, and its actual description has been questioned. We used clustering analysis to identify clinically relevant phenogroups among patients with CRS. Methods: Data for patients admitted from 1 January 2012 to 31 December 2012 were collected from the French national medico-administrative database. Patients with a diagnosis of heart failure and chronic kidney disease and at least 5 years of follow-up were included. Results: In total, 13,665 patients were included and four clusters were identified. Cluster 1 could be described as the vascular–diabetes cluster. It comprised 1930 patients (14.1%), among which 60% had diabetes, 94% had coronary artery disease (CAD), and 80% had peripheral artery disease (PAD). Cluster 2 could be described as the vascular cluster. It comprised 2487 patients (18.2%), among which 33% had diabetes, 85% had CAD, and 78% had PAD. Cluster 3 could be described as the metabolic cluster. It comprised 2163 patients (15.8%), among which 87% had diabetes, 67% dyslipidemia, and 62% obesity. Cluster 4 comprised 7085 patients (51.8%) and could be described as the low-vascular cluster. The vascular cluster was the only one associated with a higher risk of cardiovascular death (HR: 1.48 [1.32–1.66]). The metabolic cluster was associated with a higher risk of kidney replacement therapy (HR: 1.33 [1.17–1.51]). Conclusions: Our study supports a new classification of CRS based on the vascular aspect of pathophysiology differentiating microvascular or macrovascular lesions. These results could have an impact on patients' medical treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Clearance and nutrition in neonatal continuous kidney replacement therapy using the Carpediem™ system.
- Author
-
Vuong, Kim T., Vega, Molly R., Casey, Lauren, Swartz, Sarah J., Srivaths, Poyyapakkam, Osborne, Scott W., Rhee, Christopher J., Arikan, Ayse Akcan, and Joseph, Catherine
- Subjects
- *
NITROGEN metabolism , *PROTEINS , *THERAPEUTICS , *RENAL replacement therapy , *CARDIO-renal syndrome , *DATA analysis , *RECEIVER operating characteristic curves , *PARENTERAL feeding , *RESEARCH funding , *SCIENTIFIC observation , *KRUSKAL-Wallis Test , *ACUTE kidney failure , *HEMODIALYSIS , *DESCRIPTIVE statistics , *MANN Whitney U Test , *PEDIATRICS , *NUTRITIONAL status , *STATISTICS , *ANTHROPOMETRY , *DATA analysis software , *SENSITIVITY & specificity (Statistics) , *CHILDREN - Abstract
Background: Infants with kidney failure (KF) demonstrate poor growth partly due to obligate fluid and protein restrictions. Delivery of liberalized nutrition on continuous kidney replacement therapy (CKRT) is impacted by clinical instability, technical dialysis challenges, solute clearance, and nitrogen balance. We analyzed delivered nutrition and growth in infants receiving CKRT with the Cardio-Renal, Pediatric Dialysis Emergency Machine (Carpediem™). Methods: Single-center observational study of infants receiving CKRT with the Carpediem™ between June 1 and December 31, 2021. We collected prospective circuit characteristics, delivered nutrition, anthropometric measurements, and illness severity Score for Neonatal Acute Physiology-II. As a surrogate to normalized protein catabolic rate in maintenance hemodialysis, we calculated normalized protein nitrogen appearance (nPNA) using the Randerson II continuous dialysis model. Descriptive statistics, Spearman correlation coefficient, Mann Whitney, Wilcoxon signed rank, receiver operating characteristic curves, and Kruskal–Wallis analysis were performed using SAS version 9.4. Results: Eight infants received 31.9 (22.0, 49.7) days of CKRT using mostly (90%) regional citrate anticoagulation. Delivered nutritional volume, protein, total calories, enteral calories, nPNA, and nitrogen balance increased on CKRT. Using parenteral nutrition, 90 ml/kg/day should meet caloric and protein needs. Following initial weight loss of likely fluid overload, exploratory sensitivity analysis suggests weight gain occurred after 14 days of CKRT. Despite adequate nutritional delivery, goal weight (z-score = 0) and growth velocity were not achieved until 6 months after CKRT start. Most (5 infants, 62.5%) survived and transitioned to peritoneal dialysis (PD). Conclusions: Carpediem™ is a safe and efficacious bridge to PD in neonatal KF. Growth velocity of infants on CKRT appears delayed despite delivery of adequate calories and protein. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Red Blood Cell Distribution Width to Albumin Ratio for Predicting Type I Cardiorenal Syndrome in Patients with Acute Myocardial Infarction: A Retrospective Cohort Study.
- Author
-
Ruan, Liang, Xu, Shuailei, Qin, Yuhan, Tang, Huihong, Li, Xudong, Yan, Gaoliang, Wang, Dong, Tang, Chengchun, and Qiao, Yong
- Subjects
RECEIVER operating characteristic curves ,CARDIO-renal syndrome ,ERYTHROCYTES ,ACUTE kidney failure ,LOGISTIC regression analysis - Abstract
Purpose: Red blood cell distribution width to albumin ratio (RAR) is a novel inflammatory biomarker that independently predicts adverse cardiovascular events and acute kidney injury. This study aimed to assess the predictive value of RAR for cardio-renal syndrome type I (CRS-I) risk in acute myocardial infarction (AMI) patients. Patients and methods: This study retrospectively enrolled 551 patients who were definitively diagnosed as AMI between October 2021 and October 2022 at the Affiliated Zhongda Hospital of Southeast University. Participants were divided into two and four groups based on the occurrence of CRS-I and the quartiles of RAR, respectively. Demographic data, laboratory findings, coronary angiography data, and drug utilization were compared among the groups. Logistic regression and receiver operating characteristic curve (ROC) analysis were performed to identify independent risk factors for CRS-I and evaluated the predictive value of RAR for CRS-I. Results: Among the cohort of 551 patients, 103 (18.7%) developed CRS-I. Patients with CRS-I exhibited significantly elevated RAR levels compared to those without the condition, and the incidence of CRS-I correlated with escalating RAR. Univariate and multivariate logistic regression analyses identified RAR as an independent risk factor for CRS-I. ROC curves analysis demonstrated that RAR alone predicted CRS-I with an area under the curve (AUC) of 0.683 (95% CI=0.642– 0.741), which was superior to the traditional inflammatory marker C-reactive protein (CRP). Adding the variable RAR to the model for predicting the risk of CRS-I further improved the predictive value of the model from 0.808 (95% CI=0.781– 0.834) to 0.825 (95% CI=0.799– 0.850). Conclusion: RAR is an independent risk factor for CRS-I, and high levels of RAR are associated with an increased incidence of CRS-I in patients with AMI. RAR emerges as a valuable and readily accessible inflammatory biomarker that may play a pivotal role in risk stratification in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Renal Arterial and Venous Doppler in Cardiorenal Syndrome: Pathophysiological and Clinical Insights.
- Author
-
Barone, Roberta, Di Terlizzi, Vito, Goffredo, Giovanni, Paparella, Domenico, Brunetti, Natale Daniele, and Iacoviello, Massimo
- Subjects
CARDIO-renal syndrome ,KIDNEY diseases ,ACUTE kidney failure ,CARDIOVASCULAR diseases ,CHRONIC kidney failure ,VASCULAR resistance - Abstract
In recent decades, there has been considerable effort in investigating the clinical utility of renal Doppler measurements in both cardiovascular and renal disorders. In particular, a measure of renal arterial resistance, the renal resistive index (RRI), has been demonstrated to predict chronic kidney disease progression and acute kidney injury in different clinical settings. Furthermore, it is linked to a poorer prognosis in individuals suffering from chronic heart failure. Examining the renal venous flow through pulsed Doppler can offer additional insights into renal congestion and cardiovascular outcomes for these patients. This review seeks to summarize the existing data concerning the clinical significance of arterial and venous renal Doppler measurements across various cardiovascular and renal disease contexts. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Demographic trends of cardiorenal and heart failure deaths in the United States, 2011–2020.
- Author
-
Shearer, Joseph J., Hashemian, Maryam, Nelson, Robert G., Looker, Helen C., Chamberlain, Alanna M., Powell-Wiley, Tiffany M., Pérez-Stable, Eliseo J., and Roger, Véronique L.
- Subjects
- *
HEART failure , *CARDIO-renal syndrome , *RACE , *AGE groups , *NOSOLOGY - Abstract
Background: Heart failure (HF) and kidney disease frequently co-occur, increasing mortality risk. The cardiorenal syndrome results from damage to either the heart or kidney impacting the other organ. The epidemiology of cardiorenal syndrome among the general population is incompletely characterized and despite shared risk factors with HF, differences in mortality risk across key demographics have not been well described. Thus, the primary goal of this study was to analyze annual trends in cardiorenal-related mortality, evaluate if these trends differed by age, sex, and race or ethnicity, and describe these trends against a backdrop of HF mortality. Methods and findings: The Centers for Disease Control and Prevention Wide-ranging ONline Data for Epidemiologic Research database was used to examine cardiorenal- and HF-related mortality in the US between 2011and 2020. International Classification of Diseases, 10 Revision codes were used to classify cardiorenal-related deaths (I13.x) and HF-related deaths (I11.0, I13.0, I13.2, and I50.x), among decedents aged 15 years or older. Decedents were further stratified by age group, sex, race, or ethnicity. Crude and age-adjusted mortality rates (AAMR) per 100,000 persons were calculated. A total of 97,135 cardiorenal-related deaths and 3,453,655 HF-related deaths occurred. Cardiorenal-related mortality (AAMR, 3.26; 95% CI: 3.23–3.28) was significantly lower than HF-related mortality (AAMR, 115.7; 95% CI: 115.6–115.8). The annual percent change (APC) was greater and increased over time for cardiorenal-related mortality (2011–2015: APC, 7.1%; 95% CI: 0.7–13.9%; 2015–2020: APC, 19.7%, 95% CI: 16.3–23.2%), whereas HF-related mortality also increased over that time period, but at a consistently lower rate (2011–2020: APC, 2.4%; 95% CI: 1.7–3.1%). Mortality was highest among older and male decedents for both causes. Cardiorenal-related deaths were more common in non-Hispanic or Latino Blacks compared to Whites, but similar rates were observed for HF-related mortality. A larger proportion of cardiorenal-related deaths, compared to HF-related deaths, listed cardiorenal syndrome as the underlying cause of death (67.0% vs. 1.2%). Conclusions: HF-related deaths substantially outnumber cardiorenal-related deaths; however, cardiorenal-related deaths are increasing at an alarming rate with the highest burden among non-Hispanic or Latino Blacks. Continued surveillance of cardiorenal-related mortality trends is critical and future studies that contain detailed biomarker and social determinants of health information are needed to identify mechanisms underlying differences in mortality trends. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Independent and joint associations of monocyte to high-density lipoprotein-cholesterol ratio and body mass index with cardiorenal syndrome: insights from NHANES 2003–2020.
- Author
-
Lin, Junjie, Li, Zixin, Xu, Jiamin, Pan, Mengshan, Yin, Tongle, Wang, Jiadong, Sun, Qinghua, Zheng, Weijun, and Chen, Rucheng
- Subjects
- *
CARDIO-renal syndrome , *BODY mass index , *BLOOD cholesterol , *HEALTH & Nutrition Examination Survey , *DISEASE risk factors , *CHRONIC kidney failure , *CHOLESTERYL ester transfer protein - Abstract
Background: With the development of pathophysiology, cardiorenal syndrome (CRS), a complex and severe disease, has received increasing attention. Monocyte to high-density lipoprotein-cholesterol ratio (MHR) and body mass index (BMI) are independent risk factors for cardiovascular diseases, but their association with CRS remains unexplored. This study aims to explore the independent and joint effects of MHR and BMI on CRS. Methods: We included 42,178 NHANES participants. The determination of CRS referred to the simultaneous presence of cardiovascular disease (identified through self-report) and chronic kidney disease (eGFR < 60 mL/min per 1.73 m²). We employed multivariate weighted logistic regression to evaluate the odds ratio (OR) and 95% confidence interval (CI) for the independent and joint associations of MHR and BMI with CRS. We also conducted restricted cubic spines to explore nonlinear associations. Results: The prevalence of CRS was 3.45% among all participants. An increase in both MHR and BMI is associated with a higher risk of CRS (MHR: OR = 1.799, 95% CI = 1.520–2.129, P < 0.001, P-trend < 0.001; BMI: OR = 1.037, 95% CI = 1.023–1.051, P < 0.001). Individuals who simultaneously fall into the highest quartile of MHR and have a BMI of 30 or more face the highest risk of CRS compared to those in the lowest MHR quartile with a BMI of less than 25 (OR = 3.45, 95% CI = 2.40–4.98, P < 0.001). However, there is no interactive association between MHR and BMI with CRS. Conclusions: Higher MHR and BMI are associated with higher odds of CRS. MHR and BMI can serve as tools for early prevention and intervention of CRS, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Serial direct sodium removal in patients with heart failure and diuretic resistance.
- Author
-
Rao, Veena S., Ivey‐Miranda, Juan B., Cox, Zachary L., Moreno‐Villagomez, Julieta, Ramos‐Mastache, Daniela, Neville, Daniel, Balkcom, Natasha, Asher, Jennifer L., Bellumkonda, Lavanya, Bigvava, Tamar, Shaburishvili, Tamaz, Bartunek, Jozef, Wilson, F. Perry, Finkelstein, Fredrick, Maulion, Christopher, Turner, Jeffrey M., and Testani, Jeffrey M.
- Subjects
- *
BRAIN natriuretic factor , *HEART failure patients , *DIURETICS , *CARDIO-renal syndrome - Abstract
Aims: Loop diuretics may exacerbate cardiorenal syndrome (CRS) in heart failure (HF). Direct sodium removal (DSR) using the peritoneal membrane, in conjunction with complete diuretic withdrawal, may improve CRS and diuretic resistance. Methods and results: Patients with HF requiring high‐dose loop diuretics were enrolled in two prospective, single‐arm studies: RED DESERT (n = 8 euvolaemic patients), and SAHARA (n = 10 hypervolaemic patients). Loop diuretics were withdrawn, and serial DSR was utilized to achieve and maintain euvolaemia. At baseline, participants required a median 240 mg (interquartile range [IQR] 200–400) oral furosemide equivalents/day, which was withdrawn in all participants during DSR (median time of DSR 4 weeks [IQR 4–6]). Diuretic response (queried by formal 40 mg intravenous furosemide challenge and 6 h urine sodium quantification) increased substantially from baseline (81 ± 37 mmol) to end of DSR (223 ± 71 mmol, p < 0.001). Median time to re‐initiate diuretics was 87 days, and the median re‐initiation dose was 8% (IQR 6–10%) of baseline. At 1 year, diuretic dose remained substantially below baseline (30 [IQR 7.5–40] mg furosemide equivalents/day). Multiple dimensions of kidney function such as filtration, uraemic toxin excretion, kidney injury, and electrolyte handling improved (p < 0.05 for all). HF‐related biomarkers including N‐terminal pro‐B‐type natriuretic peptide, carbohydrate antigen‐125, soluble ST2, interleukin‐6, and growth differentiation factor‐15 (p < 0.003 for all) also improved. Conclusions: In patients with HF and diuretic resistance, serial DSR therapy with loop diuretic withdrawal was feasible and associated with substantial and persistent improvement in diuretic resistance and several cardiorenal parameters. If replicated in randomized controlled studies, DSR may represent a novel therapy for diuretic resistance and CRS. Clinical Trial Registration: RED DESERT (NCT04116034), SAHARA (NCT04882358). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. The Effect of Empagliflozin on Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway in Patients with Type 2 Cardiorenal Syndrome.
- Author
-
Pei Zhou, Xiangyu Tang, Yunxia Deng, Rong Wu, Yuan Yi, Hao Deng, and Qiongjiao Cao
- Subjects
- *
CARDIO-renal syndrome , *HEART failure , *MAJOR adverse cardiovascular events , *EMPAGLIFLOZIN , *DOPPLER echocardiography , *TYPE 2 diabetes , *ENZYME-linked immunosorbent assay - Abstract
Background: Empagliflozin (EMPA) demonstrates cardioprotective effects on the patients with heart failure, but its effects in cardiorenal syndrome (CRS) remain unspecified. The purpose of the exploratory study was to investigate the effect of EMPA on patients with type 2 CRS and type 2 diabetes mellitus (DM). Methods: This study was a randomized trial of patients with type 2 CRS and DM done between December 2020 and January 2022. Patients were randomly allocated to the control group and the EMPA group using EMPA as an add-on treatment. Serum interleukin 6 (IL-6), janus kinase 2 (JAK-2), and signal transducer and activator of transcription 3 (STAT-3) concentrations were measured in 102 patients with CRS and healthy individuals without any disease using enzyme-linked immunosorbent assay before and after treatment. The evaluation of renal function was measured by immunoturbidimetry, and cardiac function was estimated by doppler echocardiography. Rates of adverse events and major adverse cardiac events (MACE) were documented. Results: The results showed that EMPA decreased the level of IL-6 but increased the level of JAK-2 and STAT-3 in patients. Additionally, the results suggest EMPA significantly reduced the incidence of MACE compared to the control group, while the rate of adverse events did not significantly differed. Conclusions: Our study suggested that the cardiorenal benefits conferred by EMPA might be driven by anti-inflammatory effects, cooperated with the activation of JAK2/STAT3 signaling pathways, leading to modest short-term improvements in patients with type 2 CRS. The overall safety and low complication make EMPA a significant choice for clinical application. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. First Description of Novel End-Organ Effects by Speed Modulation Using the Aortix™ Device.
- Author
-
Bhandari, Ajay, Dunham, Alden, Bassily, Emmanuel, Mohanty, Bibhu D., and Wu, Robby
- Subjects
- *
CARDIO-renal syndrome , *ACCELERATION (Mechanics) , *SPEED , *HEART assist devices - Abstract
Aortix™ is a novel percutaneous mechanical circulatory support device designed to facilitate diuresis in patients with cardiorenal syndrome. We describe for the first time the development of end-organ hypoperfusion from excess blood acceleration at the nominal setting and demonstrate through temporal-perfusion marker curves, the potential for speed modulation to optimize results. This will inform future device development and investigation of patient-specific device titration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. The potential role of hydrogen sulfide in regulating macrophage phenotypic changes via PINK1/parkin-mediated mitophagy in sepsis-related cardiorenal syndrome.
- Author
-
Chen, Yuxuan, Cao, Wei, Li, Bin, Qiao, Xiaofei, Wang, Xiangdong, Yang, Guang, and Li, Siying
- Subjects
- *
CARDIO-renal syndrome , *HYDROGEN sulfide , *PHENOTYPIC plasticity , *MACROPHAGES , *REACTIVE oxygen species , *LIPOPOLYSACCHARIDES - Abstract
Sepsis is one of major reasons of cardiorenal syndrome type 5 (CRS-5), resulting in irreversible tissue damage and organ dysfunction. Macrophage has been demonstrated to play key role in the pathophysiology of sepsis, highlighting the need to identify therapeutic targets for modulating macrophage phenotype in sepsis. In this study, a rapid-releasing hydrogen sulfide (H2S) donor NaSH, and a slow-releasing H2S compound S-propargyl-cysteine (SPRC) which is derived from garlic, have been studied for the immune-regulatory effects on macrophages. The NaSH and SPRC showed the potential to protect the heart and kidney from tissue injury induced by LPS. The immunohistochemistry of F4/80+ revealed that the infiltration of macrophages in the heart and kidney tissues of LPS-treated mice was reduced by NaSH and SPRC. In addition, in the LPS-triggered inflammatory cascade of RAW264.7 macrophage cells, NaSH and SPRC exhibited significantly inhibitory effects on the secretion of inflammatory cytokines, production of reactive oxygen species (ROS), and regulation of the macrophage phenotype from M1-like to M2-like. Moreover, autophagy, a crucial process involved in the elimination of impaired proteins and organelles during oxidative stress and immune response, was induced by NaSH and SPRC in the presence of LPS stimulation. Consequently, there was an increase in the number of mitochondria and an improvement in mitochondrial membrane potential. This process was mainly mediated by PINK1/Parkin pathway mediated mitophagy. These results demonstrated that the immunoregulatory effects of H2S donors were through the PINK1/Parkin-mediated mitophagy pathway. Overall, our study provided a new therapeutic direction in LPS-induced cardiorenal injury. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Cardiorenal Syndromes and Their Role in Water and Sodium Homeostasis.
- Author
-
BURYSKOVA SALAJOVA, Kristina, MALIK, Jan, and VALERIANOVA, Anna
- Subjects
CARDIO-renal syndrome ,HOMEOSTASIS ,EXTRACELLULAR fluid ,PATHOLOGICAL physiology ,RENIN-angiotensin system - Abstract
Sodium is the main osmotically active ion in the extracellular fluid and its concentration goes hand in hand with fluid volume. Under physiological conditions, homeostasis of sodium and thus amount of fluid is regulated by neural and humoral interconnection of body tissues and organs. Both heart and kidneys are crucial in maintaining volume status. Proper kidney function is necessary to excrete regulated amount of water and solutes and adequate heart function is inevitable to sustain renal perfusion pressure, oxygen supply etc. As these organs are bidirectionally interconnected, injury of one leads to dysfunction of another. This condition is known as cardiorenal syndrome. It is divided into five subtypes regarding timeframe and pathophysiology of the onset. Hemodynamic effects include congestion, decreased cardiac output, but also production of natriuretic peptides. Renal congestion and hypoperfusion leads to kidney injury and maladaptive activation of renin-angiotensin-aldosterone system and sympathetic nervous system. In cardiorenal syndromes sodium and water excretion is impaired leading to volume overload and far-reaching negative consequences, including higher morbidity and mortality of these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. The Potential Ameliorative Effect of Empagliflozin on Myocardium in Cardiorenal Syndrome 3 via Targeting Mitophagy and Mitochondrial Biogenesis in Adult Male Albino Rat Model: Biochemical, Histological and Immunohistochemical Study.
- Author
-
Yousry, Marwa Mohamed and Alghandour, Sarah Mohammed
- Subjects
STAINS & staining (Microscopy) ,LABORATORY rats ,CARDIO-renal syndrome ,MITOCHONDRIAL dynamics ,HEMATOXYLIN & eosin staining ,MYOCARDIAL reperfusion ,SODIUM-glucose cotransporters - Abstract
Background: Cardiorenal syndrome-3 (CRS3) represents the pathological link between kidneys and heart where acute kidney injury (AKI) causes serious cardiac abnormalities. Disrupted mitochondrial dynamics are the main contributor to CRS3. Mitophagy plays a protective role through reducing mitochondrial damage and oxidative-stress. Empagliflozin (EMPA), a sodium-glucose cotransporter-2 inhibitor, has therapeutic effects on cardiac and renal pathology with or without diabetes type-2 through anti-oxidative, anti-inflammatory &anti-apoptotic mechanisms. Aim of work: Evaluating EMPA probable reparative impact on the myocardium of adult male albino rat CRS3-model using biochemical, histological &immunohistochemical studies. Materials and Methods: Twenty-eight adult male albino rats (3 months old, 200g weight) were divided into: control & experimental (subjected to AKI) groups. AKI-rats were subdivided equally into 3 subgroups, AKI, AKI/recovery & AKI/EMPA (received daily oral 20mg/kg EMPA 1week after renal surgery for 3 weeks). Results: AKI induced a significant rise in serum urea, creatinine, cardiac TNF-α, H
2 O2 levels, P62, cytochrome-C area percentage, besides a non-significant increase in Mn-SOD level, mitophagy-PINK1/PARKIN &mitochondrial biogenesis-PGC1α gene expression, LC3B, sirtuin-3 area percentage &a significant decrease in ATP level. Myocardium showed darkly stained shrunken nuclei, disrupted transverse striations by H&E stain and minimal collagen deposition by Masson's trichrome. AKI/recovery recorded further reduction in ATP, Mn-SOD levels, PINK1/PARKIN, PGC1α expression, LC3B, sirtuin-3 area percentage and evident increase in H2O2 level, P62, cytochrome-C area percentage with marked myocardial affection & more collagen deposition. AKI/EMPA demonstrated an obvious improvement in the previously mentioned results. Conclusion: EMPA ameliorated CRS3-induced myocardial damage through the inhibition of inflammation & mitochondrial oxidative-stress in addition to mitophagy &mitochondrial biogenesis activation. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
40. Case report: Challenging kidney transplantation in an adolescent patient with tetralogy of Fallot
- Author
-
Ante Jakšić, Berislav Barbalić, Lidija Orlić, Željko Župan, Božidar Vujičić, Antun Gršković, Tanja Ćelić, Ivana Koraca Chinchella, Neven Čače, Sanja Flajšman-Raspor, Ivan Bubić, Josip Španjol, and Dean Markić
- Subjects
cardio-renal syndrome ,congenital heart disease ,chronic renal insufficiency ,kidney transplantation ,tetralogy of Fallot ,Medicine (General) ,R5-920 - Abstract
Tetralogy of Fallot is the most common cyanotic congenital heart disease. This severe disorder of cardiac physiology can impair renal function and lead to the development of cardiorenal syndrome and eventually to end-stage renal disease. Kidney transplantation may be the best option for renal replacement treatment in patients with tetralogy of Fallot, but only after correcting cardiac abnormalities and optimizing cardiac functions, all of which require a multidisciplinary approach. We report the first case of kidney transplantation in an adolescent patient with tetralogy of Fallot. Our findings confirms that kidney transplantation is a valuable treatment option in selected congenital heart disease cases.
- Published
- 2024
- Full Text
- View/download PDF
41. Pulmonary hypertension in heart failure: the good, the bad, and the ugly.
- Author
-
Rosenkranz, Stephan, Hoeper, Marius M, and Maron, Bradley A
- Subjects
PULMONARY artery diseases ,HEART valve diseases ,CARDIO-renal syndrome ,RIGHT ventricular dysfunction ,CARDIAC patients ,HEART failure - Abstract
The article discusses the impact of pulmonary hypertension (PH) on patients with heart failure (HF). PH is frequently seen in HF patients and is associated with increased mortality. The article highlights the updated definitions of PH and pre-capillary PH provided by the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines. The study by Fauvel et al. demonstrates that the refined definitions of PH and pre-capillary PH are valid and that patients with values above the new thresholds are at increased risk of adverse outcomes. The article also mentions the need for further research on the prognostic implications and therapeutic options for PH in HF patients. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
42. Refocusing cardio-renal problems: the cardiovascular-kidney-metabolic syndrome and the chronic cardiovascular-kidney disorder.
- Author
-
Zoccali, Carmine and Zannad, Faiez
- Subjects
- *
SCIENTIFIC literature , *CHRONIC kidney failure , *ANGIOTENSIN converting enzyme , *CARDIO-renal syndrome , *CARDIOVASCULAR system , *HEART failure - Abstract
The article discusses the concept of cardio-renal problems, specifically the cardiovascular-kidney-metabolic syndrome (CKM) and the chronic cardiovascular-kidney disorder (CCKD). The CKM is characterized by a cluster of metabolic risk factors that impact the kidneys and cardiovascular system, while the CCKD focuses on concomitant cardiovascular and kidney problems independently of their chronology. Both concepts emphasize the complexity of managing patients with these conditions and the need for interdisciplinary care models, lifestyle modifications, and innovative treatment strategies. The article also highlights the importance of addressing social determinants of health and conducting comprehensive research to better understand these conditions. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
43. C‐reactive protein, inflammation and short‐term mortality in acute heart failure.
- Author
-
Cotter, Gad, Pagnesi, Matteo, and Davison, Beth
- Subjects
- *
BRAIN natriuretic factor , *HEART failure , *DISEASE risk factors , *LEFT ventricular hypertrophy , *CARDIO-renal syndrome , *ACUTE coronary syndrome - Abstract
This article discusses the association between C-reactive protein (CRP) and heart failure (HF). CRP is a marker of inflammation and has been found to be elevated in patients with HF. The article highlights a study that shows the addition of CRP to a risk score improves the prediction of 30-day mortality in patients with acute HF. The study suggests that inflammation may play a stronger role in acute HF compared to chronic HF. The findings of this study may lead to further research on anti-inflammatory therapies for acute HF. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
44. Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients With Cardio Renal Syndrome With Severe Renal Impairment (CARDIOMEMS)
- Author
-
CHU Arnaud de Villeneuve MONTPELLIER
- Published
- 2023
45. Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1
- Author
-
Jonathan Samuel Chavez Iñiguez, Dr.
- Published
- 2023
46. Renal Denervation in Patients With Chronic Heart Failure
- Published
- 2023
47. Association Between Renal and Right Cardiac Functions After Urinary Sodium Depletion Following Cardiac Surgery (DECONGEST)
- Published
- 2023
48. Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
- Published
- 2023
49. Treatment with Rasburicase in Hospitalized Patients with Cardiorenal Syndrome: Old Treatment, New Scenario.
- Author
-
Melero, Rosa, Torroba-Sanz, Beatriz, Goicoechea, Marian, Sousa-Casasnovas, Iago, Barrio, Jose María, García-Prieto, Ana María, Rodriguez-Benitez, Patrocinio, García-González, Xandra, and Sanjurjo-Sáez, María
- Subjects
- *
CARDIO-renal syndrome , *HOSPITAL patients , *BRAIN natriuretic factor , *TUMOR lysis syndrome , *GLOMERULAR filtration rate , *KIDNEYS , *ARACHNOID cysts - Abstract
Cardiorenal syndrome (CRS) involves joint dysfunction of the heart and kidney. Acute forms share biochemical alterations like hyperuricaemia (HU) with tumour lysis syndrome (TLS). The mainstay treatment of acute CRS with systemic overload is diuretics, but rasburicase is used in TLS to prevent and treat hyperuricaemia. An observational, retrospective study was performed to assess the effectiveness and safety of a single dose of rasburicase in hospitalized patients with cardiorenal syndrome, worsening renal function and uric acid levels above 9 mg/dL. Rasburicase improved diuresis and systemic congestion in the 35 patients included. A total of 86% of patients did not need to undergo RRT, and early withdrawal was possible in the remaining five. Creatinine (Cr) decreased after treatment with rasburicase from a peak of 3.6 ± 1.27 to 1.79 ± 0.83 mg/dL, and the estimated glomerular filtration rate (eGFR) improved from 17 ± 8 to 41 ± 20 mL/min/1.73 m2 (p = 0.0001). The levels of N-terminal type B Brain Natriuretic Peptide (Nt-ProBNP) and C-reactive protein (CRP) were also significantly reduced. No relevant adverse events were detected. Our results show that early treatment with a dose of rasburicase in patients with CRS and severe HU is effective to improve renal function and systemic congestion, avoiding the need for sustained extrarenal clearance, regardless of comorbidities and ventricular function. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Bioinformatics analysis of the microRNA genes associated with type 2 cardiorenal syndrome.
- Author
-
Zong, Yani, Hu, Yuexin, Zheng, Mengdi, and Wang, Zhi
- Subjects
CARDIO-renal syndrome ,GENE ontology ,GENE expression ,HEPATORENAL syndrome ,HEART failure ,MICRORNA ,CELLULAR signal transduction ,BIOINFORMATICS - Abstract
Background: MicroRNAs (miRNAs) are important regulatory factors in the normal developmental stages of the heart and kidney. However, it is currently unclear how miRNA is expressed in type 2 cardiorenal syndrome (CRS). This study aimed to detect the differential expression of miRNAs and to clarify the main enrichment pathways of differentially expressed miRNA target genes in type 2 CRS. Methods: Five cases of healthy control (Group 1), eight of chronic heart failure (CHF, Group 2) and seven of type 2 CRS (Group 3) were enrolled, respectively. Total RNA was extracted from the peripheral blood of each group. To predict the miRNA target genes and biological signalling pathways closely related to type 2 CRS, the Agilent miRNA microarray platform was used for miRNA profiling and bioinformatics analysis of the isolated total RNA samples. Results: After the microarray analysis was done to screen for differentially expressed circulating miRNAs among the three different groups of samples, the target genes and bioinformatic pathways of the differential miRNAs were predicted. A total of 38 differential miRNAs (15 up- and 23 down-regulated) were found in Group 3 compared with Group 1, and a total of 42 differential miRNAs (11 up- and 31 down-regulated) were found in Group 3 compared to Group 2. According to the Gene Ontology (GO) function and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis, the top 10 lists of molecular functions, cellular composition and biological processes, and the top 30 signalling pathways of predicted gene targets of the differentially expressed miRNAs were discriminated among the three groups. Conclusion: Between the patients with CHF and type 2 CRS, miRNAs were differentially expressed. Prediction of target genes of differentially expressed miRNAs and the use of GO function and KEGG pathway analysis may reveal the molecular mechanisms of CRS. Circulating miRNAs may contribute to the diagnosis of CRS, and further and larger studies are needed to enhance the robustness of our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.